{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T23:21:11Z","timestamp":1795044071530,"version":"4.10.2"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Real-world data were collected to examine antimicrobial resistance (AMR) prevalence, treatment patterns, and clinical outcomes among female patients with uncomplicated urinary tract infection (uUTI) in Germany. Data were from a retrospective physician-based chart review completed by physicians treating patients with uUTI. Non-pregnant women aged\u2009\u2265\u200912\u00a0years, with a uUTI diagnosis, an <jats:italic>E. coli-<\/jats:italic>positive urine culture between January 2017\u2013December 2019, and susceptibility test results for\u2009\u2265\u20094 drug classes were eligible. Patients were stratified into three cohorts by drug class susceptibility: susceptible to all (SUS), resistant to one or two drug classes (DR1\/2), and resistant to\u2009\u2265\u20093 (MDR) drug classes tested. Among 386 eligible patients [SUS (67.1%); DR1\/2 (29.0%); MDR (3.9%)], AMR prevalence was highest for FMIs (18.3%) and lowest for fluoroquinolones (5.2%). The most prescribed drugs were fosfomycin in SUS (44.0%), DR1\/2 (41.4%), and fluoroquinolones in MDR (40.0%). Treatment for uUTI failed for 8.8% of patients; failure was more likely in MDR versus SUS [adjusted odds ratio [95% CI]\u2009=\u20094.21 [1.14\u20131.50]; P\u2009=\u20090.031); incidence of recurrent infection in the 6-months post-index period was higher in DR1\/2 versus SUS. These findings may have implications for empiric prescribing, suggesting an unmet need for new treatments.<\/jats:p>","DOI":"10.1038\/s41598-023-38919-8","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T10:02:02Z","timestamp":1690365722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Escherichia coli resistance, treatment patterns and clinical outcomes among females with uUTI in Germany: a retrospective physician-based chart review study"],"prefix":"10.1038","volume":"13","author":[{"given":"Kurt G.","family":"Naber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Wagenlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kresken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Y.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryaline","family":"Catillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anamika","family":"Khanal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruni","family":"Mulgirigama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish V.","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinyoung","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny S.","family":"Mitrani-Gold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"38919_CR1","doi-asserted-by":"publisher","first-page":"5S","DOI":"10.1016\/S0002-9343(02)01054-9","volume":"113","author":"B Foxman","year":"2002","unstructured":"Foxman, B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. Am. J. Med. 113, 5S-13S (2002).","journal-title":"Am. J. Med."},{"key":"38919_CR2","doi-asserted-by":"publisher","first-page":"175628721983217","DOI":"10.1177\/1756287219832172","volume":"11","author":"M Medina","year":"2019","unstructured":"Medina, M. & Castillo-Pino, E. An introduction to the epidemiology and burden of urinary tract infections. Ther. Adv. Urol. 11, 1756287219832172. https:\/\/doi.org\/10.1177\/1756287219832172 (2019).","journal-title":"Ther. Adv. Urol."},{"key":"38919_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jgar.2021.11.008","volume":"28","author":"F Wagenlehner","year":"2021","unstructured":"Wagenlehner, F. et al. A global perspective on improving patient care in uncomplicated urinary tract infection: Expert consensus and practical guidance. J. Glob. Antimicrob. Resist. 28, 18\u201329 (2021).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"38919_CR4","unstructured":"Bonkat, G. et al. EAU Guidelines on Urological Infections. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-Guidelines-on-Urological-infections-2023.pdf (2023)."},{"key":"38919_CR5","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1159\/000486138","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz, J. et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: Part 1. Urol. Int. 100, 263\u2013270 (2018).","journal-title":"Urol. Int."},{"key":"38919_CR6","first-page":"415","volume":"108","author":"FM Wagenlehner","year":"2011","unstructured":"Wagenlehner, F. M. et al. Uncomplicated urinary tract infections. Dtsch. Arztebl. Int. 108, 415\u2013423 (2011).","journal-title":"Dtsch. Arztebl. Int."},{"key":"38919_CR7","first-page":"277","volume":"40","author":"CL Ventola","year":"2015","unstructured":"Ventola, C. L. The antibiotic resistance crisis: Part 1: Causes and threats. Pharmacol. Ther. 40, 277\u2013283 (2015).","journal-title":"Pharmacol. Ther."},{"key":"38919_CR8","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1179\/2047773215Y.0000000030","volume":"109","author":"F Prestinaci","year":"2015","unstructured":"Prestinaci, F., Pezzotti, P. & Pantosti, A. Antimicrobial resistance: A global multifaceted phenomenon. Pathog. Glob. Health 109, 309\u2013318 (2015).","journal-title":"Pathog. Glob. Health"},{"key":"38919_CR9","unstructured":"Federal Office of Consumer Protection and Food Safety (Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V.). GERMAP 2015\u2014Report on the Consumption of Antimicrobials and the Spread of Antimicrobial Resistance in Human and Veterinary Medicine in Germany. Antiinfectives Intelligence, Rheinbach, 2016. https:\/\/www.bvl.bund.de\/SharedDocs\/Downloads\/05_Tierarzneimittel\/germap2015_EN.pdf?__blob=publicationFile&v=52016 (2016)."},{"key":"38919_CR10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-2490-12-33","volume":"12","author":"G Schmiemann","year":"2012","unstructured":"Schmiemann, G., Gagyor, I., Hummers-Pradier, E. & Bleidorn, J. Resistance profiles of urinary tract infections in general practice\u2014An observational study. BMC Urol. 12, 33 (2012).","journal-title":"BMC Urol."},{"key":"38919_CR11","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1186\/s12879-017-2789-7","volume":"17","author":"M Seitz","year":"2017","unstructured":"Seitz, M., Stief, C. & Waidelich, R. Local epidemiology and resistance profiles in acute uncomplicated cystitis (AUC) in women: A prospective cohort study in an urban urological ambulatory setting. BMC Infect. Dis. 17, 685 (2017).","journal-title":"BMC Infect. Dis."},{"key":"38919_CR12","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJ Murray","year":"2022","unstructured":"Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"38919_CR13","unstructured":"OECD. Stemming the Superbug Tide. https:\/\/www.oecd.org\/els\/health-systems\/Stemming-the-Superbug-Tide-Policy-Brief-2018.pdf (2018)."},{"key":"38919_CR14","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 9.0, 2019. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_9.0_Breakpoint_Tables.pdf (2019)."},{"key":"38919_CR15","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1159\/000487645","volume":"100","author":"J Kranz","year":"2018","unstructured":"Kranz, J. et al. The 2017 update of the German clinical guideline on epidemiology, diagnostics, therapy, prevention, and management of uncomplicated urinary tract infections in adult patients: Part II: Therapy and prevention. Urol. Int. 100, 271\u2013278 (2018).","journal-title":"Urol. Int."},{"key":"38919_CR16","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.eururo.2008.05.010","volume":"54","author":"KG Naber","year":"2008","unstructured":"Naber, K. G., Schito, G., Botto, H., Palou, J. & Mazzei, T. Surveillance study in Europe and Brazil on clinical aspects and Antimicrobial Resistance Epidemiology in Females with Cystitis (ARESC): Implications for empiric therapy. Eur. Urol. 54, 1164\u20131175 (2008).","journal-title":"Eur. Urol."},{"key":"38919_CR17","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/j.ijantimicag.2009.04.012","volume":"34","author":"GC Schito","year":"2009","unstructured":"Schito, G. C. et al. The ARESC study: An international survey on the antimicrobial resistance of pathogens involved in uncomplicated urinary tract infections. Int. J. Antimicrob. Agents 34, 407\u2013413 (2009).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"38919_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1093\/jac\/dkg280","volume":"52","author":"G Kahlmeter","year":"2003","unstructured":"Kahlmeter, G. & Menday, P. Cross-resistance and associated resistance in 2478 Escherichia coli isolates from the Pan-European ECO\u00b7 SENS Project surveying the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections. J. Antimicrob. Chemother. 52, 128\u2013131 (2003).","journal-title":"J. Antimicrob. Chemother."},{"key":"38919_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s00120-009-2145-7","volume":"49","author":"FM Wagenlehner","year":"2010","unstructured":"Wagenlehner, F. M. et al. Clinical aspects and epidemiology of uncomplicated cystitis in women. German results of the ARESC Study. Urologe A 49, 253\u2013261 (2010).","journal-title":"Urologe A"},{"key":"38919_CR20","doi-asserted-by":"publisher","first-page":"e103","DOI":"10.1093\/cid\/ciq257","volume":"52","author":"K Gupta","year":"2011","unstructured":"Gupta, K. et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 52, e103-120. https:\/\/doi.org\/10.1093\/cid\/ciq257 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"38919_CR21","doi-asserted-by":"publisher","first-page":"7656752","DOI":"10.1155\/2018\/7656752","volume":"2018","author":"DS Lee","year":"2018","unstructured":"Lee, D. S., Lee, S. J. & Choe, H. S. Community-acquired urinary tract infection by Escherichia coli in the era of antibiotic resistance. Biomed. Res. Int. 2018, 7656752. https:\/\/doi.org\/10.1155\/2018\/7656752 (2018).","journal-title":"Biomed. Res. Int."},{"key":"38919_CR22","first-page":"41","volume":"1","author":"A Foroughi","year":"2020","unstructured":"Foroughi, A. & Ramezan-Ghanbari, S. The frequency of Stx1 and Stx2 genes in uropathogenic Escherichia coli isolated from patients in Kermanshah, Iran. Epigenetics 1, 41\u201346 (2020).","journal-title":"Epigenetics"},{"key":"38919_CR23","unstructured":"EMA. Disabling and Potentially Permanent Side Effects Lead to Suspension or Restrictions of Quinolone and Fluoroquinolone Antibiotics. https:\/\/www.ema.europa.eu\/en\/documents\/referral\/quinolone-fluoroquinolone-article-31-referral-disabling-potentially-permanent-side-effects-lead_en.pdf (2019)."},{"key":"38919_CR24","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 7.1, 2017. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_7.1_Breakpoint_Tables.pdf (2017)."},{"key":"38919_CR25","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 8.1, 2018. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Consultation\/2018\/Information_for_NACs_-_Redefining_antimicrobial_susceptibility_testing_categories.pdf (2018)."},{"key":"38919_CR26","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Breakpoint Tables for Interpretation of MICs and Zone Diameters. Version 11.0, 2021. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Breakpoint_tables\/v_11.0_Breakpoint_Tables.pdf (2021)."},{"key":"38919_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ijantimicag.2011.09.013","volume":"39","author":"G Kahlmeter","year":"2012","unstructured":"Kahlmeter, G. & Poulsen, H. O. Antimicrobial susceptibility of Escherichia coli from community-acquired urinary tract infections in Europe: The ECO.SENS study revisited. Int. J. Antimicrob. Agents 39, 45\u201351 (2012).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"38919_CR28","first-page":"w14660","volume":"148","author":"S Erb","year":"2018","unstructured":"Erb, S. et al. Basic patient characteristics predict antimicrobial resistance in E. coli from urinary tract specimens: A retrospective cohort analysis of 5246 urine samples. Swiss Med. Wkly. 148, w14660 (2018).","journal-title":"Swiss Med. Wkly."},{"key":"38919_CR29","first-page":"Doc04","volume":"13","author":"J Zweigner","year":"2018","unstructured":"Zweigner, J., Meyer, E., Gastmeier, P. & Schwab, F. Rate of antibiotic prescriptions in German outpatient care\u2014Are the guidelines followed or are they still exceeded?. GMS Hyg. Infect. Control 13, Doc04 (2018).","journal-title":"GMS Hyg. Infect. Control"},{"key":"38919_CR30","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.urology.2015.05.033","volume":"86","author":"M Hisano","year":"2015","unstructured":"Hisano, M. et al. The bacterial spectrum and antimicrobial susceptibility in female recurrent urinary tract infection: How different they are from sporadic single episodes?. Urol. J. 86, 492\u2013497 (2015).","journal-title":"Urol. J."},{"key":"38919_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1476-0711-8-27","volume":"8","author":"C Aypak","year":"2009","unstructured":"Aypak, C., Altunsoy, A. & Duzgun, N. Empiric antibiotic therapy in acute uncomplicated urinary tract infections and fluoroquinolone resistance: A prospective observational study. Ann. Clin. Microbiol. Antimicrob. 8, 27. https:\/\/doi.org\/10.1186\/1476-0711-8-27 (2009).","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"38919_CR32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.cmi.2019.10.016","volume":"26","author":"N Daneman","year":"2020","unstructured":"Daneman, N. et al. Fluoroquinolone use for uncomplicated urinary tract infections in women: A retrospective cohort study. Clin. Microbiol. Infect. 26, 613\u2013618. https:\/\/doi.org\/10.1016\/j.cmi.2019.10.016 (2020).","journal-title":"Clin. Microbiol. Infect."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38919-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38919-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T10:06:39Z","timestamp":1690365999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-38919-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["38919"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-38919-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K.G.N. discloses consultancy fees from AdamedPharma, Biomerieux, Bionorica, Eumedica, GSK, Immunotek, OM Pharma, and MIP\/Rosen Pharma. F.W. is an advisor of GSK and a principal investigator in a GSK-sponsored study. M.K is a partner and CEO of Antiinfectives Intelligence GmbH, a research organization providing services to pharmaceutical companies. W.Y.C., M.C., M.S.D., L.Y., and A.K. are employees of Analysis Group, Inc., which has received funding from GSK to conduct the study. A.M., A.V.J., S.J., and F.S.M-G. are employees of and shareholders in GSK. Aspects of this work were previously presented at ECCMID 2022 in the form of posters and summary slides. These were entitled: \u201cAntimicrobial Resistance Patterns and Patient Characteristics Among Females With Uncomplicated Urinary Tract Infection in Germany: A Physician-Based Chart Review\u201d and \u201cTreatment Patterns and Outcomes in Female Outpatients With Uncomplicated Urinary Tract Infection in Germany: A Physician-Based Chart Review\u201d.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"12077"}}